Trials / Completed
CompletedNCT02010788
Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 523 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat urinary incontinence in patients with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB) not adequately controlled by anticholinergic drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | botulinum toxin Type A | Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice. |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2016-07-01
- Completion
- 2016-07-01
- First posted
- 2013-12-13
- Last updated
- 2016-09-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02010788. Inclusion in this directory is not an endorsement.